Analysts are intrested in these 5 stocks: ( (GENI) ), ( (CF) ), ( (MMM) ), ( (NKE) ) and ( (SNPS) ). Here is a breakdown of their recent ratings and the rationale behind them.
Genius Sports is back on analysts’ radar, with Samuel Nielsen initiating coverage at Buy and a USD8 target for December 2027. Despite the stock’s sharp underperformance this year and concerns over its Legend acquisition and prediction markets, he argues the risk–reward is attractive, pointing to strong growth, improving cash flow and a cheap valuation versus peers.
The analyst highlights Genius Sports’ role as a global B2B data and adtech platform, serving hundreds of leagues, sportsbooks and brands with official data and advertising tools. He expects high-teens revenue growth and solid EBITDA conversion through 2028, notes upcoming regulatory and earnings catalysts, and believes the market is not fully pricing in upside from prediction markets or successful execution at Legend.
CF Industries is described as a rare “quality compounder” in a commodity business, with James Hooper initiating coverage at Buy and a USD162 price target, implying solid upside. Since its 2005 IPO, CF has massively grown shareholder value, driven by a simple formula of expanding nutrient output per share while using excess cash for low-cost projects and aggressive buybacks.
Hooper expects that formula to keep working, modelling nutrient per share growth above 8% annually through 2030 as favourable cycle conditions support nitrogen prices and U.S. corn farmers’ profitability. Even as fertilizer prices gradually normalize, he sees CF reinvesting billions into the Blue Point ammonia JV and buybacks while holding net debt near zero, supporting his positive view on the stock’s compounding potential.
3M is moving back into favour as Varun Govindaraj upgrades the stock to Hold (Market-Perform) with a USD171 target. After meetings with management, he now believes 3M’s R&D has been structurally overhauled into an “R&D factory” that focuses on disciplined portfolio management, better data use and returns on innovation, supporting slightly higher long-term organic growth.
He also sees a tailwind from an early-stage short-cycle industrial recovery linked to AI-related capital spending, which could aid 3M’s traditionally cyclical businesses. Margin expansion is another pillar, with operating margins targeted near 25% by 2026, while PFAS legal risk appears more manageable than previously thought, potentially reducing a key overhang that had pressured the stock for years.
Nike, by contrast, faces a more cautious outlook as Lorraine Hutchinson downgrades the shares to Sell (Underperform) with a USD30 price objective, below the current price. She sees rising risk to earnings and valuation, as Nike’s innovation efforts are being overshadowed by weakness in its classic styles and broader category and macro headwinds, leading her to cut forecasts and expect negative sales growth through fiscal 2027.
Wholesale momentum in North America is likely to slow as retailers grow more cautious, with sell-through lagging prior strong sell-in and order books at risk if new products fail to excite. In China, a strategic reset comes against a tough demand backdrop and intense competition, with weaker sports appetite and excess inventory; Hutchinson believes these pressures could keep the stock’s valuation under strain as earnings expectations fall.
Synopsys is being recast as a high-growth AI winner, with Frank Lee upgrading the stock to Buy and lifting his target to a Street-high USD700. He argues that the company’s move from its traditional “build once, sell many” IP licensing model to a royalty-based “Factory Two” approach, combined with deeper customer collaboration, will link revenue more directly to chip volumes and significantly expand its addressable market.
At the same time, Synopsys is set to benefit from a new era in electronic design automation, as agentic AI shifts tools from assisting engineers to orchestrating workflows autonomously under subscription-plus-consumption models. Lee believes these changes could push earnings growth sharply higher, justify a premium valuation multiple, and position Synopsys alongside the most sought-after AI plays in the semiconductor ecosystem.


